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Inhibitory effects of local 
anesthetics on the proteasome and 
their biological actions
Udin Bahrudin1,13, Masaki Unno2,3, Kazuya Nishio4,14, Akiko Kita4, Peili Li1, Masaru Kato5, 
Masashi Inoue6, Shunichi Tsujitani7, Takuto Murakami8,9, Rina Sugiyama2, Yasushi Saeki10, 
Yuji Obara2,3, Keiji Tanaka10, Hiroshi Yamaguchi8,9, Isao Sakane11, Yasushi Kawata11, Toshiyuki 
Itoh11, Haruaki Ninomiya12, Ichiro Hisatome1 & Yukio Morimoto4
Local anesthetics (LAs) inhibit endoplasmic reticulum-associated protein degradation, however the 
mechanisms remain elusive. Here, we show that the clinically used LAs pilsicainide and lidocaine bind 
directly to the 20S proteasome and inhibit its activity. Molecular dynamic calculation indicated that 
these LAs were bound to the β5 subunit of the 20S proteasome, and not to the other active subunits, 
β1 and β2. Consistently, pilsicainide inhibited only chymotrypsin-like activity, whereas it did not inhibit 
the caspase-like and trypsin-like activities. In addition, we confirmed that the aromatic ring of these LAs 
was critical for inhibiting the proteasome. These LAs stabilized p53 and suppressed proliferation of p53-
positive but not of p53-negative cancer cells.
Local anesthetics (LAs) are clinically important for treatment of arrhythmias, control of pain, and suppression 
of seizures1–3. They work by blocking voltage-gated Na+ channels responsible for initiating action potentials in 
excitable cells to cause the electrical conduction block of the heart and neurons as their acute effect4–7. LAs reach 
the binding site within the channel pore between the selective filter and the channel gates to modify the channel 
conformation through interactions of their aromatic ring with the aromatic group of amino acid residues located 
in the Na+ channel gate8, 9.
Recently, LAs such as quinidine, mexiletine and aprindine have been reported to stabilize Na+ channels 
(Nav1.5)10, 11 as well as human ether-go-go-related gene (hERG) K+ channels12, and Kir6.2 proteins13, when 
administered for a long time. Channel proteins with a short half-life time such as Nav1.514, cystic fibrosis trans-
membrane regulator15, gap junction channel connexin 4316, 17, Kv1.518, Kir6.213, and hERG12 are degraded through 
the ubiquitin-proteasome system (UPS). LAs have been suggested to have some effects on the UPS based on the 
results of microarray analyses showing up-regulation of channel proteins with a short half-life time by these 
agents19.
P53 is the key molecule for regulating cell proliferation, which is degraded through UPS20, and its accumu-
lation is well-known to induce cellular apoptosis21. Among the anticancer properties of various medicines, it 
is reported that they modulate the expression of p53 and induce apoptosis, thus LAs-induced modification of 
the expression of p53 may contribute to developing the new anticancer agents. On the other hand, an increased 
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expression of p53 may explain their harmful effects on the heart. An increase in p53 induces left ventricular dila-
tation and dysfunction in mice defficient in MDM2, an E3 ligase for p53. Furthermore, it has been demonstrated 
that p53 is critically involved in pressure overload–induced cardiac dysfunction22. Indeed, in clinical settings, 
such as in the Cardiac Arrhythmia Suppression Trial (CAST study)23, for preventing arrhythmias, long term 
treatment with Na+ channel blockers was reported deterioration of the cardiac function accompanied by death of 
patients with myocardial infarction, suggesting Na+ channel blockers may show deleterious effects on the heart 
via affecting proteasome activity. Thus, aiming at the development of new anticancer agents as well as at the atten-
uation of the harmful action of LAs, we explored the action of LAs on the proteasome.
LAs commonly have an aromatic ring with an amido bond. LAs can share this common structure with 
authentic proteasome inhibitors targeting the chymotrypsine-like site of the 20S proteasome such as MG132 and 
PS-34124, suggesting that the aromatic ring of the LAs may interact not only with Na+ channels but also with the 
chymotrypsine-like site of the 20S proteasome. Thus, LAs can access the chymotrypsine-like site of the 20S protea-
some to inhibit it. The 20S proteasome consists of four heptameric rings (two outer α rings and two inner β rings), 
which are made up of seven structurally related α and β subunits, respectively, displaying an α1–7β1–7β1–7α1–7  
organization25, 26. Three β1, β2, and β5 subunits of the inner β-rings contain catalytically active threonine resi-
dues at their N termini, in which the β1, β2, and β5 subunits are associated with caspase-like, trypsin-like, and 
chymotrypsin-like activities, respectively. Two pairs of these three active sites face the interior of the cylinder and 
reside in a chamber formed by the two β rings.
The initial purpose of the present study was to determine whether and how the LAs inhibit the UPS to stabilize 
the short-lived proteins degraded via proteasomes. We identified the structure-based mechanism of LAs binding 
to the chymotrypsine-like site of the β5 subunit of the 20S proteasome along with the common structure to exert 
its Na+ channel blocking action. We also demonstrated that LAs suppress the proliferation of MKN45 cells.
Results
Inhibition of the 20S Proteasome Activity. In an attempt to clarify the mechanism of action of LAs, 
we examined whether LAs inhibited the activity of the 20S proteasome in vitro. LAs with an aromatic ring, such 
as pilsicainide and lidocaine, inhibited 20S proteasome activity although the extent of inhibition was signifi-
cantly lower than that attained with MG132 or bortezomib (Fig. 1a). IC50 values were 4.1 ± 2.4 nM, 1.1 ± 1.8 nM, 
3.5 ± 1.5 μM, 23 ± 0.2 μM, 20 ± 2.5 μM, and 14 ± 6.3 μM for MG132, bortezomib, pilsicainide, lidocaine, 4-F, and 
mexiletine, respectively (Explanation of 4-F is described later and supplementary information). Neither the Ca2+ 
channel blocker verapamil which contains two aromatic rings, nor the K+ channel blocker E-4031, affected the 
activity of the 20S proteasome (Fig. 1a). Tetrodotoxin (TTX), a Na+ channel blocker without an aromatic ring, 
did not inhibit 20S proteasome activity, either (Fig. 1a and Supplementary Fig. S1), suggesting that the single 
aromatic ring of LAs might play a role in the blockade of proteasome activity. Actually, quinidine, mexiletine and 
aprindine have a single aromatic ring similar to lidocaine and pilsicainide, and both aprindine and mexiletine 
inhibit the 20S proteasome, although we previously reported that bepridil (Supplementary Fig. S1), a Na+ chan-
nel blocker with two aromatic rings, did not show the inhibitory action on the proteasome27. To substantiate this 
idea, we examined whether modification of the aromatic ring of LAs could also affect 20S proteasome activity. 
Fluorinated derivatives 2-F, 3-F, 4-F, 2,4-F and 2,6-F with altered electronic properties of the compound28, 29  
(Supplementary Table S1 and Fig. S1) partially inhibited the chymotrypsin-like activity of the 20S proteasome 
(Fig. 1a,b), while M-3 did not (Fig. 1a,b). IC50 values for 2-F, 3-F, 4-F, 2,4-F and 2,6-F were 21.5 ± 46.8 μM, 
20.5 ± 21.8 μM, 23 ± 0.2 μM, 23 ± 22 μM, and 28 ± 33 μM, respectively. We also conducted a [3H]-pilsicainide 
binding assay in the absence and presence of pilsicainide, lidocaine, 4-F as well as M-3. The [3H]-pilsicainide 
binding assay revealed binding of pilsicainide, lidocaine, and 4-F to the 20S proteasome with Kd = 1.0 ± 2.8 μM, 
Kd = 21.2 ± 3.5 μM and Kd = 20 ± 3.2 μM, respectively, whereas no binding capacity of M-3 was observed (Fig. 1c).
Docking Simulations of LAs binding to the 20S proteasome. Automated docking simulations were 
performed to find the binding mode of pilsicainide to the active site region of bovine proteasomes. Hetényi 
and van der Spoel have reported a considerable reliability automated docking simulations with the program 
AutoDock 3.0 in predicting the binding mode of a ligand molecule to a protein without prior knowledge about its 
binding site30. In this study, we have adopted a two-step method to search a plausible binding site of pilsicainide: 
firstly, binding results were classified into clusters roughly by their positions and secondly, a cluster was selected 
that was significantly populated and contained a binding conformation of low energy. Docking simulations of 
pilsicainide against two segments of the β ring (β1-β2-β3 section and β4-β5-β6 section) showed a significantly 
low docked energy in a conformational cluster in β4-β5-β6 but not in β1-β2-β3 (Fig. 2a). The energetically most 
stable and most populated cluster was found in the pocket-like structure of the β5 subunit (Fig. 2b). For pilsic-
ainide binding, one sufficient cluster was found in a grid map around the β5 subunit and no sufficient clusters 
were found for a grid map around β4 and β6. The cluster found in a grid map around β5 contained 17-binding 
conformations, including a binding conformation with the lowest energy. The binding mode and the binding 
conformation with the lowest energy are shown in Fig. 2b. Through interactions of its aromatic ring with the aro-
matic residue of Tyr136 and of its amido group with both Tyr113 and Gly129, pilsicainide occupied a groove (S1′ 
pocket) formed by three β-strands at the subunit interface of β4 and β5; i.e., Val26-Met28 of β4, Arg120-Ser122 
and Thr125-Val128 of β5, which is located in the vicinity of the nucleophilic attacking residue Thr1 of the subunit 
(S1 pocket). The KI value (dissociation constant of inhibitor) estimated from the binding energy was determined 
to be 1 μM, which was a little lower than that from the binding experiment. In contrast to pilsicainide, which 
showed a well populated and low binding-energy cluster, other analogs tested did not showed such a signifi-
cant binding clusters. The 4-F derivative was energetically favored but showed less populated clusters against the 
β4-β5-β6 section compared to pilsicainide, while lidocaine showed only less energetically favored and less pop-
ulated clusters compared to pilsicainide (Fig. 2c). The conformation of the lowest binding energy in the cluster 
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that lays in the binding pocket showed binding-free energy and a KI value for lidocaine of −7 kcal/mol and 20 μM 
(Fig. 2a and c), respectively. This suggests that lidocaine has less affinity to the binding site of pilsicainide, which 
was consistent with the results from their inhibitory action on 20S proteasome activities.
Trypsin-like and caspase-like activities of the wild-type 20S proteasome were not inhibited by pilsicainide 
(Supplementary Fig. S2). These results were in accordance with the finding that pilsicainide binds only to the β5 
catalytic subunit of the 20S proteasome.
Stabilization of Proteins by LAs and MG132. Inhibition of the 20S proteasome results in stabilization 
of proteins degraded through the UPS. The tumor suppressor p53 is well known to be degraded through the UPS. 
Like MG132, both pilsicainide and lidocaine increased the expression of p53-FLAG in COS7 cells together with a 
concomitant accumulation of its ubiquitinated form (Supplementary Fig. S3a). This p53 is ubiquitinated primar-
ily by E3 ligase Mdm231 and its C438A mutant works as a dominant negative form. Co-expression of the C438A 
mutant of Mdm2 with p53-FLAG abolished the effects of pilsicainide, lidocaine and MG132, providing further 
evidence for proteasome inhibition by these LAs (Supplementary Fig. S3b). 4-F partially increased the protein 
expression of p53-FLAG, while M-3 failed to affect it (Fig. 3a,b).
Figure 1. Effects of LAs on 20S proteasome activity and binding to the 20S proteasome. (a) Effects of LAs and 
other related chemical agents (■: pilsicainide; ▼: lidocaine; ∆: MG132; ♦: bortezomib; □: verapamil; ○: 
E-4031; ◊: TTX; ▲: 4-F; ●: M-3) on 20S proteasome activity in vitro. Each point represents the mean ± SEM 
of more than 7 determinations. 20S proteasome activities were expressed relative to their values in the absence 
of drugs (100%). The calculated IC50 values were 4.1 ± 2.4 nM, 1.1 ± 1.8 nM, 3.5 ± 1.5 μM, 23 ± 0.2 μM, 
20 ± 2.5 μM, 14 ± 6.3 μM for MG132, bortezomib, pilsicainide, lidocaine, 4F, and mexiletine, respectively. 
(b) Inhibitory action of pilsicainide, 2-F, 3-F, 4-F, 2,4-F, 2,6-F and M-3 at 10 μM (left) and 100 μM (right) on 
the chymotrypsin-like activity of the proteasome. (c) Inhibition of binding of [3H]-pilsicainide to the 20S 
proteasome by cold pilsicainide, 4-F, M-3 and lidocaine in vitro. Each point represents the mean ± SEM of more 
than 7 determinations. The binding fraction of [3H]-pilsicainide to the 20S proteasome was expressed relative to 
the values in the absence of cold pilsicainide, 4-F, M-3 or lidocaine (100%). Kd values for pilsicainide, lidocaine, 
and 4-F are1.0 ± 2.8 μM, 21.2 ± 3.5 μM, and 4-F, respectively, whereas no binding capacity of M-3 was observed.
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Given these results, we examined the effects of LAs on the proliferation of MKN45 gastric cancer cells that 
express p53. Both pilsicainide and lidocaine increased the p53 protein level in MKN45 cells in a dose-dependent 
manner. 4-F increased p53 a little and M-3 failed to increase it (Fig. 3c,d).
Suppression of Proliferation of Cancer Cells. Furthermore, pilsicainide and lidocaine suppressed pro-
liferation of MKN45 cells in a dose-dependent manner, whereas M-3 did not inhibit their proliferation (Fig. 4a). 
These effects of pilsicainide and lidocaine were not observed in Kato III gastric cancer cells that do not express 
p53 (Fig. 4b). To test the inhibitory action of LAs on the proliferation of MKN45 cells in vivo, MKN45 cells 
were pretreated with lidocaine and then transplanted into the intestine of SOD SKID mice. Lidocaine treatment 
resulted in suppression of tumor growth (Fig. 4c).
Discussion
In this work, we demonstrated that LAs stabilized the short-lived protein degraded in the cytosol by proteasomes, 
and LAs with an aromatic ring, such as pilsicainide, bound directly to the proteasome β5 subunit and inhibited 
Figure 2. Predicted binding mode of LAs to the proteasome. (a) Docking simulations of pilsicainide against 
two parts of the β-subunit ring. (b) The binding mode of pilsicainide in the β5 subunit. The approximate 
position of S1 site pocket is designated. CPK model of pilsicainide and the surrounding protein matrix surface 
(left panel). Subunits β4 and β5 are colored yellow and orange, respectively. Amino acid residues surrounding 
the pilsicainide molecule and the nucleophilic active site residue of Thr1 are represented by the stick model and 
named (right panel). Green broken lines denote putative hydrogen bonds between the ligand and the protein. 
(c) Docking simulations of pilsicainide and its derivative 4-F, and lidocaine against β4-β5-β6 subunits.
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its chymotrypsin-like activity, although the affinity to S1′ pocket differed between pilsicainide and lidocaine. 
Modification of the aromatic ring of pilsicainide attenuated its inhibitory action on the 20S proteasome.
The eukaryotic 20S proteasome has at least three different types of the specificity against substrate pol-
ypeptides, i.e., caspase-like (for acidic amino acid residues), trypsin-like (for basic amino acid residues), and 
chymotrypsin-like (for hydrophobic and aromatic amino acid residues) specificities32. These three specificities 
have been assigned to three active subunits β1, β2, and β5, respectively33, determined by using synthesized fluoro-
genic peptides in vitro. The subunit β5 has the chymotrypsin-like activity and mutations in the active site in this 
subunit were shown to be lethal or to disturb cell growth33. The predicted binding site of pilsicainide was apart 
from the nucleophilic attacking residue Thr1 of the subunit. From crystallographic25, 34 and modeling studies35, it 
was reported that inhibitors specific for the proteasome mainly targeted the S1 site.
In our estimated model, however, pilsicainide bound to the groove that is located in the vicinity of S1 site, as 
shown in Fig. 2. This groove is presumably acting as the S1′ site of proteinase as an analogy of chymotrypsin, and 
the inhibitor is disturbing the substrate binding. Thus, this S1′ site could be another target for designing a new 
inhibitor for the proteasome. The inhibitory action of LAs on the chymotrypsin-like activity of the 20S proteas-
ome may come from their common structure. LAs essentially bear an aromatic ring and an amido group in their 
structure not only for conferring lipophilicity to a drug that allows it to pass through membranes, but also for 
CH-π or π-stacked binding to the aromatic group of amino acid residues to block Na+ channels activities. Our 
estimated model demonstrated that pilsicainide bound to the S1′ site via interaction of its aromatic ring with 
Tyr136 (CH-π or π-stacked binding) and/or interaction with the amido group of Tyr113 and Gly129 (hydrogen 
bonding). It is well-known that fluoride closely mimics the steric requirement of hydrogen at the enzyme receptor 
site, but its strong electronegativity significantly alters the reactivity of neighboring centers. Therefore, fluorinated 
derivatives have been a tool for the investigation of molecular interactions of the chemicals with amino acid 
residues. Since aromatic residues are capable of forming π-electron interactions with the aromatic drug portion, 
which are known to be crucial for high-affinity LA block of Na+ channel, aromaticity is crucial for Na+ channel 
function and pharmacology. Fluorinated derivatives of pilsicainide revealed a decrease in electron-density of their 
aromatic ring, which perturb not only the interaction with the aromatic group of Tyr136, but also interaction 
between the amido groups of Tyr113 and Gly129 (Fig. 2b), leading to less potent inhibition of the 20S proteasome 
Figure 3. Pilsicainide and lidocaine increase transfected and endogenous p53. (a), (b) Dose-dependent effects 
of MG132 and LAs on ubiquitinated p53-FLAG protein. Cell lysates were analyzed by Western blot analysis 
(a). Quantitative analysis of p53-FLAG stability using densitometry is shown in (b). Each point was expressed 
relative to the values in the absence of drugs (100%). (c), (d) Dose-dependent effects of LAs on endogenous p53 
expression in MKN45 cells. MKN45 cells were cultured for 24 h in the presence of pilsicainide, lidocaine, 4-F, 
M-3 or MG132. Cell lysates were analyzed by Western blot analysis (c). Quantitative analysis of the protein level 
of endogenous p53 was conducted using densitometry (d).
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activity (Fig. 1b) in comparison with pilsicainide. Thus, either the M-3 compound analogue of pilsicainide or 
their fluorinated derivatives attenuated both their bind to and block of the 20S proteasome (Fig. 1c), as well as 
their stabilization of p53-FLAG (Fig. 3). Taken together, the aromatic ring of LAs played a pivotal role by occu-
pying the groove that is located in the vicinity of S1 site to interfere with the access of hydrophobic and aromatic 
amino acid residues of the targeted peptide to this site.
In this study, we found that LAs with an aromatic ring such as pilsicainide and lidocaine inhibit the proteas-
ome activity. The 20S proteasome is a potential target in cancer therapy36, 37. However, these LAs are not very good 
inhibitors because their binding affinities were relatively low. Although based on the structure of pilsicainide, it 
will be possible to design anti-cancer drugs, that are hardly realized. Na+ channel blockers are used widely in the 
world for treating arrhythmias in patients with heart disease. According to the CAST study23, it is well-recognized 
that Na+ channel blockers significantly increase the mortality rate in patients with myocardial infarction, while 
its underlying mechanism remains unknown. Accumulation of p53 in the myocardium has been reported to be 
Figure 4. Effects of LAs on cancer cells. (a) Effects of LAs on the proliferation of MKN45 cells. MKN45 
cells were cultured for 24 h in the presence of MG132, pilsicainide, lidocaine, 4-F or M-3. Proliferation of 
MKN43 was estimated by MTT assays. (b) Effects of LAs on the proliferation of MKN45 and Kato III cells 
cultured for 24 h in the presence of MG132 (10 nM), pilsicainide (1 μM) and lidocaine (20 μM). (c) In the in 
vivo experiments, lidocaine significantly decreased the proliferation of MKN45 cells dispersed among mouse 
mesenchymal cells to a similar extent as MG132.
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associated with chronic heart failure38, 39. Taken together, the present results that Na+ channel blockers, at clinical 
concentrations, increase p53 via inhibition of the proteasome, Na+ channel blockers could increase the mor-
tality rate of patients with heart failure, which may explain in part the side effects observed in the CAST study. 
Therefore, the present study may contribute to the development of new selective Na+ channel blockers without 
inhibitory actions on the proteasome via modification of the aromatic ring, and safer for patients with heart 
failure. The clinical implications of this novel action of pilsicainide should be a subject of future investigations.
Methods
Plasmids and Expression. pcDNA3/p53-FLAG was a kind gift from Dr. Nakayama (Kyushu University). 
pcDNA3/Mdm2 (C438A) was a kind gift from Dr. Yasuda (Tokyo Pharmaceutical College). pCR/CMV/hH1 
was a kind gift from Dr. Makita (Hokkaido University). COS7 cells were maintained in Dulbecco’s modified 
Eagle medium (Gibco BRL)/10% fetal bovine serum at 37 °C in a 5% CO2 incubator. Cells were transfected using 
lipofectamine (Gibco BRL) according to the instructions provided by the manufacturer. Forty-eight hours after 
transfection, cells were assayed. Proteasome inhibitors or LAs were applied 36 hours after transfection. All drugs 
except for MG132 were dissolved in culture medium or distilled water. MG132 was dissolved in dimethyl sulfox-
ide (DMSO). The final concentration of DMSO in the culture or reaction medium was equal to or less than 0.01% 
v/v. Pilsicainide was kindly provided by Daiichi Suntory Pharmaceutical Co., Ltd. (Osaka, Japan).
Western Blot Analysis and Immunoprecipitation. The same amounts (10 μg) of protein were sepa-
rated on SDS-PAGE and electro-transferred to a polyvinylidene difluoride membrane. Membranes were probed 
with antibodies against FLAG (1:1000, Cosmo Bio), GFP (1:1000, Molecular Probes), ubiquitin (1:1000, MBL) 
or β-actin (1:1000, Oncogene) and were developed using an ECL detection system. Immunoprecipitation was 
carried out in PBS/1% Triton X-100, 0.5% SDS, 0.25% sodium deoxycholate, 1 mM ethylenediaminetetraacetic 
acid (EDTA), and 10 μg/ml aprotinin, 10 μg/ml leupeptine, 10 μg/ml pepstatin and 1 mM phenylmethylsulfonyl-
fluoride for 2 h at 4 °C. Immune complexes were collected with protein G agarose (GE Healthcare Life Science) 
and bound proteins were analyzed by SDS-PAGE followed by immunoblotting.
Measurement of 20S Proteasome Activity. 20S Proteasome activity was assessed by fluorescence of free 
AMC (7-Amino-4-methylcoumarin, excitation: 380 nm, emission: 460 nm) liberated from a substrate peptide 
(Suc-Leu-Leu-Val-Tyr-MCA). The reaction mixture contained the 20S proteasome (500 μg/ml), the substrate 
peptide (10 μM) and the indicated drugs in 25 mM HEPES, 0.5 mM EDTA, 0.03% SDS, pH 7.6. The mixture 
was incubated at 37 °C for 1 h. AMC fluorescence liberated in the absence of drugs was taken as the basal value 
(100%). The fluorescence liberated in the absence of SDS was taken as the background value (0%)13. Most of the 
activity assays were conducted using an assay kit (Calbiochem), but some were conducted in hand-made buffer 
solutions.
Docking Simulation of Compounds of the Bovine 20S Proteasome. Docking simulations were per-
formed using the AutoDock program package, version 3.0.540. The crystal structure coordinates of the bovine pro-
teasome were obtained from Brookhaven Protein Databank [PDB ID: 1IRU26]. The structure coordinates of the 
fourteen β subunits located in the inner rings of the proteasome were extracted from the data file for the docking 
simulation. Missing residues in the protein structure were reconstructed using the program Swiss-PDB Viewer41. 
Polar hydrogen atoms were reconstructed using the program ‘protonate’ supplied with AutoDock distribution. 
Atomic charges and atomic solvation parameters in the protein were assigned using the programs ‘q.kollua’ and 
‘addsol’, respectively. The structure and Mulliken atomic charges of pilsicainide were calculated using Gaussian98 
(Gaussian Inc., USA). In the ligand structure used for docking, freedom of torsion at the peptide bond was frozen 
and all non-polar hydrogen atoms were merged to their bonded carbon atom. Two grid maps were generated 
to cover three proteinase active subunits; β1, β2, and β5 (designated as H, I, and L in the PDB file, respectively). 
Grid maps were generated with 0.375 Å spacing within a rectangular volume of 38.6 Å × 47.6 Å × 47.6 Å. Default 
values were used for parameters of the simulation, except for the ‘maximum number of energy evaluations’ and 
‘maximum number of generations’, both of which were set to 107. The Lamarckian genetic algorithm with the 
pseudo Solis and Wets search was used for the calculations. The results of 100 individual trials were divided into 
clusters of conformations with an rms tolerance of 1.5 Å. These clusters were aligned with the docked energy of 
each cluster, which was determined as the lowest docked energy within the cluster. The cluster with a significant 
population and the lowest docking energy was selected as the set containing the most probable binding confor-
mations. The conformation with the lowest docking energy within this set was selected as the most probable 
binding conformation.
Ligand Binding Assay. Commercially available 20S proteasome was purchased from Calbiochem. LAs and 
their derivatives at increasing concentrations (10–8 to 10–2 M) were incubated with [3H]-pilsicainide for 1 h at 
room temperature in buffer containing 50 mM HEPES supplemented with 1% bovine serum albumin (pH 7.4). 
Following the reaction termination by addition of 100% tricarboxylic acid, the bound and unbound ligands were 
separated by centrifugation. Specific binding was defined as the difference between binding capacities in the pellet 
and supernatant.
Analysis of Data on Dose-Dependent Inhibition of the 20S proteasome. Concentration depend-
ence of the effects of each drug on the stability of the short-lived protein and the 20S proteasome activity was 
fitted using the following equation:
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where, B% represents the changes in expression of the short-lived protein and the 20S proteasome activity 
induced by drugs at a given concentration of the [drug], and Bmax represents the maximum attainable reduction. 
IC50 and n are the half-maximal inhibitory concentration and Hill coefficient, respectively.
One-way ANOVA test and Student-t test were carried out to compare the groups. All data are expressed as the 
mean ±SEM. The level of statistical significance was set at p < 0.05.
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